Gabriel LÃ¡zaro-MuÃ±oz

List of Publications by Year
in descending order

69	974	471509 17	526287 27
papers	citations	h-index	g-index

78	78	78	1254
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sidman Instrumental Avoidance Initially Depends on Lateral and Basal Amygdala and Is Constrained by Central Amygdala-Mediated Pavlovian Processes. Biological Psychiatry, 2010, 67, 1120-1127.	1.3	121
2	Active vs. reactive threat responding is associated with differential c-Fos expression in specific regions of amygdala and prefrontal cortex. Learning and Memory, 2013, 20, 446-452.	1.3	71
3	Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?. Molecular Psychiatry, 2021, 26, 60-65.	7.9	54
4	Continued access to investigational brain implants. Nature Reviews Neuroscience, 2018, 19, 317-318.	10.2	38
5	Screening embryos for polygenic conditions and traits: ethical considerations for an emerging technology. Genetics in Medicine, 2021, 23, 432-434.	2.4	36
6	Endogenous GluR1â€containing AMPA receptors translocate to asymmetric synapses in the lateral amygdala during the early phase of fear memory formation: An electron microscopic immunocytochemical study. Journal of Comparative Neurology, 2010, 518, 4723-4739.	1.6	35
7	Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice. American Journal of Bioethics, 2015, 15, 3-14.	0.9	30
8	Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats.. Behavioral Neuroscience, 2006, 120, 1093-1102.	1.2	25
9	Development of an aversive Pavlovian-to-instrumental transfer task in rat. Frontiers in Behavioral Neuroscience, 2013, 7, 176.	2.0	24
10	Neuroethics of neuromodulation: An update. Current Opinion in Biomedical Engineering, 2018, 8, 45-50.	3.4	22
11	Researcher Perspectives on Ethical Considerations in Adaptive Deep Brain Stimulation Trials. Frontiers in Human Neuroscience, 2020, 14, 578695.	2.0	21
12	Lesions of lateral or central amygdala abolish aversive Pavlovian-to-instrumental transfer in rats. Frontiers in Behavioral Neuroscience, 2014, 8, 161.	2.0	20
13	Device Removal Following Brain Implant Research. Neuron, 2019, 103, 759-761.	8.1	20
14	Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians. Harvard Review of Psychiatry, 2019, 27, 53-64.	2.1	19
15	Which Results to Return: Subjective Judgments in Selecting Medically Actionable Genes. Genetic Testing and Molecular Biomarkers, 2017, 21, 184-194.	0.7	17
16	Enhance Diversity Among Researchers to Promote Participant Trust in Precision Medicine Research. American Journal of Bioethics, 2018, 18, 44-46.	0.9	17
17	DBS and Autonomy: Clarifying the Role of Theoretical Neuroethics. Neuroethics, 2021, 14, 83-93.	2.8	17
18	Psychiatric genetics researchers' views on offering return of results to individual participants. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 589-600.	1.7	17

#	Article	IF	Citations
19	MYRIAD AFTER THE PROPRIETARY DATA DILEMMA. North Carolina Journal of Law & Technology, 2014, 15, 597-637.	2.0	17
20	International Society of Psychiatric Genetics Ethics Committee: Issues facing us. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 543-554.	1.7	16
21	Child and Adolescent Psychiatristsâ€™ Perceptions of Utility and Self-rated Knowledge of Genetic Testing Predict Usage for Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 657-660.	0.5	16
22	Pediatric Deep Brain Stimulation for Dystonia: Current State and Ethical Considerations. Cambridge Quarterly of Healthcare Ethics, 2020, 29, 557-573.	0.8	13
23	Researcher Views on Changes in Personality, Mood, and Behavior in Next-Generation Deep Brain Stimulation. AJOB Neuroscience, 2023, 14, 287-299.	1.1	13
24	Genomic Contraindications for Heart Transplantation. Pediatrics, 2017, 139, .	2.1	12
25	Pressing ethical issues in considering pediatric deep brain stimulation for obsessive-compulsive disorder. Brain Stimulation, 2021, 14, 1566-1572.	1.6	12
26	The Fiduciary Relationship Model for Managing Clinical Genomic â€œIncidentalâ€•Findings. Journal of Law, Medicine and Ethics, 2014, 42, 576-589.	0.9	11
27	Should We Be Concerned About Preserving Agency and Personal Identity in Patients With Adaptive Deep Brain Stimulation Systems?. AJOB Neuroscience, 2017, 8, 73-75.	1.1	11
28	Treatment-resistant psychotic symptoms and the 15q11.2 BP1â€“BP2 (Burnside-Butler) deletion syndrome: case report and review of the literature. Translational Psychiatry, 2020, 10, 42.	4.8	11
29	Automatic Placement of Genomic Research Results in Medical Records: Do Researchers Have a Duty? Should Participants Have a Choice?. Journal of Law, Medicine and Ethics, 2015, 43, 827-842.	0.9	11
30	Researcher Perspectives on Data Sharing in Deep Brain Stimulation. Frontiers in Human Neuroscience, 2020, 14, 578687.	2.0	11
31	Preventing discrimination based on psychiatric risk biomarkers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 159-171.	1.7	10
32	Researchersâ€™ Ethical Concerns About Using Adaptive Deep Brain Stimulation for Enhancement. Frontiers in Human Neuroscience, 2022, 16, 813922.	2.0	10
33	Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntingtonâ€™s Disease. American Journal of Psychiatry, 2018, 175, 400-407.	7.2	9
34	Psychiatric genomics researchersâ€™ perspectives on best practices for returning results to individual participants. Genetics in Medicine, 2020, 22, 345-352.	2.4	9
35	Parental Attitudes Toward Deep Brain Stimulation in Adolescents with Treatment-Resistant Conditions. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 97-103.	1.3	8
36	Treatment-resistant psychotic symptoms and early-onset dementia: A case report of the 3q29 deletion syndrome. Schizophrenia Research, 2020, 224, 195-197.	2.0	8

#	Article	IF	Citations
37	Neuroethics at 15: Keep the Kant but Add More Bacon. AJOB Neuroscience, 2019, 10, 97-100.	1.1	7
38	Return of results in a global survey of psychiatric genetics researchers: practices, attitudes, and knowledge. Genetics in Medicine, 2021, 23, 298-305.	2.4	7
39	Scientific Social Responsibility: Lessons From the Corporate Social Responsibility Movement. American Journal of Bioethics, 2015, 15, 64-66.	0.9	6
40	Manipulating Human Memory Through Reconsolidation: Stones Left Unturned. AJOB Neuroscience, 2016, 7, 244-247.	1.1	6
41	Is Real-Time ELSI Realistic?. AJOB Empirical Bioethics, 2020, 11, 134-144.	1.6	6
42	Strategies to mitigate impacts of the COVID-19 pandemic on patients treated with deep brain stimulation. Brain Stimulation, 2020, 13, 1642-1643.	1.6	5
43	Neural Safeguards against Global Impacts of Memory Modification on Identity: Ethical and Practical Considerations. AJOB Neuroscience, 2021, 12, 45-48.	1.1	5
44	Perceptions of best practices for return of results in an international survey of psychiatric genetics researchers. European Journal of Human Genetics, 2021, 29, 231-240.	2.8	4
45	Treatment Search Fatigue and Informed Consent. AJOB Neuroscience, 2021, 12, 77-79.	1.1	4
46	Patient, Caregiver, and Decliner Perspectives on Whether to Enroll in Adaptive Deep Brain Stimulation Research. Frontiers in Neuroscience, 2021, 15, 734182.	2.8	4
47	Responsible Translation of Psychiatric Genetics and Other Neuroscience Developments: In Need of Empirical Bioethics Research. American Journal of Bioethics, 2017, 17, 33-35.	0.9	3
48	Ethical Analysis of â€œMind Readingâ€•or â€œNeurotechnological Thought Apprehensionâ€‰ Keeping Potential Limitations in Mind. AJOB Neuroscience, 2019, 10, 32-34.	1.1	3
49	Perceptions of Deep Brain Stimulation for Adolescents with Obsessive-Compulsive Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 109-117.	1.3	3
50	LEGAL AND ETHICAL IMPLICATIONS OF CRISPR APPLICATIONS IN PSYCHIATRY. North Carolina Law Review, 2019, 97, 1359-1398.	1.0	3
51	Alienation, Quality of Life, and DBS for Depression. AJOB Neuroscience, 2018, 9, 223-225.	1.1	2
52	Could Genetic Enhancement Really Lead to Obsolescence?. American Journal of Bioethics, 2019, 19, 34-36.	0.9	2
53	The need for attention to the ethical, legal, and social implications of advances in psychiatric genomics. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 521-522.	1.7	2
54	Ethical and Social Considerations for Increasing Use of DTC Neurotechnologies. AJOB Neuroscience, 2019, 10, 183-185.	1.1	2

#	Article	IF	Citations
55	Implications of secondary findings for clinical contexts. , 2020, , 155-201.		2
56	Testimonial injustice: considering caregivers in paediatric behavioural healthcare. Journal of Medical Ethics, 2021, 47, 738-739.	1.8	2
57	Ethical, Legal, and Social Implications. , 2020, , 431-442.		2
58	Clinical and Psychosocial Factors Considered When Deciding Whether to Offer Deep Brain Stimulation for Childhood Dystonia. Neuromodulation, 2023, 26, 1646-1652.	0.8	2
59	Capacities and Limitations of Using Polygenic Risk Scores for Reproductive Decision Making. American Journal of Bioethics, 2022, 22, 42-45.	0.9	2
60	Research Comparing iPSC-Derived Neural Organoids to Ex Vivo Brain Tissue of Postmortem Donors: Identity After Life?. AJOB Neuroscience, 2022, 13, 111-113.	1.1	2
61	Operationalizing Agency in Brain Computer Interface (BCI) Research. AJOB Neuroscience, 2021, 12, 203-205.	1.1	1
62	CHALLENGES FOR IMPLEMENTING A PTSD PREVENTIVE GENOMIC SEQUENCING PROGRAM IN THE U.S. MILITARY. Case Western Reserve Journal of International Law, 2015, 47, 87-113.	0.0	1
63	Trust in Neuroethics. AJOB Neuroscience, 2022, 13, 33-35.	1.1	1
64	Response to Open Peer Commentaries on â€œLooking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choiceâ€• American Journal of Bioethics, 2015, 15, W6-W9.	0.9	0
65	GENOME EDITING IN THE CONTEXT OF MENTAL HEALTH DISORDERS. European Neuropsychopharmacology, 2019, 29, S1050.	0.7	0
66	THE GENOMICS OF HIGHLY TREATMENT RESISTANT SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S1006-S1007.	0.7	0
67	The Ethics of Getting Ahead When All Heads Are Enhanced. AJOB Neuroscience, 2020, 11, 256-258.	1.1	0
68	Reconceptualizing Triage to Incorporate Principles of Risk and Uncertainty: An Example from Deep Brain Stimulation Patients with Treatment-Resistant Disorders. American Journal of Bioethics, 2020, 20, 207-209.	0.9	0
69	Commercialization, Consent, and the Neural Device Industry. AJOB Neuroscience, 2022, 13, 65-67.	1.1	0